A high-profile heart drug program involving AstraZeneca and Ionis suffered a surprise failure, according to results discussed around the European Society of Cardiology meeting. The setback affects the Wainua (eplontersen) gene-silencing effort in heart disease. The failure raised questions among clinicians and investors about what went wrong in patient outcomes and how concomitant therapies may have influenced the trial signal. Analysts also noted how closely related RNA interference competitors are watching for implications. The development adds pressure to AstraZeneca’s cardiovascular pipeline as rival approaches compete for label expansion in congestive and inherited heart conditions. Separately, commentary around the trial points to complex trial conduct and background treatments as potential explanations for the disappointing outcome, rather than a clear statement on drug biology.